PAICS抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hela cells, K562 cells, Raji cells, Jurkat cells, Primary antibody: P08597(PAICS Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P08597(PAICS Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08597(PAICS Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

PAICS (phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazole succinocarboxamide synthetase) is a bifunctional enzyme encoded by the *PAICS* gene, playing a critical role in the *de novo* purine biosynthesis pathway. It catalyzes two sequential steps in purine ring formation: the carboxylation of phosphoribosylaminoimidazole (AIR) and the subsequent succinocarboxamide synthesis. As purines are essential for DNA/RNA synthesis and cellular energy metabolism, PAICS is vital for rapidly proliferating cells, including cancer cells.

PAICS overexpression has been implicated in various cancers (e.g., breast, prostate, lung) and is linked to tumor progression, metastasis, and poor prognosis. Its oncogenic role extends beyond purine synthesis; PAICS interacts with signaling pathways like MYC and HIF-1α, promoting cancer cell survival and adaptation to hypoxia. These attributes make PAICS a potential therapeutic target and biomarker.

PAICS antibodies are tools to study its expression, localization, and function in cancer biology. They enable detection via Western blot, immunohistochemistry (IHC), or immunofluorescence (IF), aiding research on PAICS-driven oncogenic mechanisms. Recent studies also explore neutralizing PAICS activity with inhibitors or antibodies to disrupt purine synthesis in preclinical cancer models. However, clinical applications remain exploratory, requiring further validation of PAICS targeting strategies.